PPA Differences Between Small And Large Sponsors
Source: Life Science Leader
By Industry Standard Research
The overwhelming majority of respondents (85%) at small and emerging biopharma companies do not have preferred provider agreements (PPAs) for Phase 2/3 outsourcing. This is a striking comparison to the wider audience of clinical development outsourcers — 83 percent of large sponsors and 47 percent of midsize sponsors said they have PPAs in place. What does this mean? With only about one-in-10 respondents bound by PPAs, it is a CRO’s market.
access the Magazine Article!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.
Subscribe to Life Science Leader
X
Subscribe to Life Science Leader
This website uses cookies to ensure you get the best experience on our website. Learn more